Work

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

Year: 2003

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(02)00836-5

Authors: J Verweij, A van Oosterom, J.-Y Blay, I Judson, S Rodenhuis, W van der Graaf, J Radford, A Le Cesne, P.C.W Hogendoorn, E.D di Paola, M Brown, O.S Nielsen

Institutions: Erasmus MC, Erasmus MC Cancer Institute, Universitair Ziekenhuis Leuven, Inserm, Centre Léon Bérard, Royal Marsden Hospital, The Netherlands Cancer Institute, University Medical Center Groningen, The Christie Hospital, Institut Gustave Roussy, Leiden University Medical Center, European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer, Aarhus Municipality

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2115811601

FWCI: 32.81

Cites: 22

Cited by: 405

Related to: 9